Literature DB >> 27523500

Toward the Reliable Diagnosis of DSM-5 Premenstrual Dysphoric Disorder: The Carolina Premenstrual Assessment Scoring System (C-PASS).

Tory A Eisenlohr-Moul1, Susan S Girdler1, Katja M Schmalenberger1, Danyelle N Dawson1, Pallavi Surana1, Jacqueline L Johnson1, David R Rubinow1.   

Abstract

OBJECTIVE: Despite evidence for the validity of premenstrual dysphoric disorder (PMDD) and the inclusion of the disorder in DSM-5, variable diagnostic practices compromise the construct validity of the diagnosis and threaten the clarity of efforts to understand and treat its underlying pathophysiology. In an effort to hasten and streamline the translation of the DSM-5 criteria for PMDD into terms compatible with existing research practices, the authors present the development and initial validation of the Carolina Premenstrual Assessment Scoring System (C-PASS). The C-PASS (available as a worksheet, Excel macro, and SAS macro) is a standardized scoring system for making DSM-5 PMDD diagnoses using two or more months of daily symptom ratings with the Daily Record of Severity of Problems (DRSP).
METHOD: Two hundred women recruited for retrospectively reported premenstrual emotional symptoms provided two to four months of daily symptom ratings on the DRSP. Diagnoses made by expert clinician and by the C-PASS were compared.
RESULTS: Agreement of C-PASS diagnosis with expert clinical diagnosis was excellent; overall correct classification by the C-PASS was estimated at 98%. Consistent with previous evidence, retrospective reports of premenstrual symptom increases were a poor predictor of prospective C-PASS diagnosis.
CONCLUSIONS: The C-PASS is a reliable and valid companion protocol to the DRSP that standardizes and streamlines the complex, multilevel diagnosis of DSM-5 PMDD. Consistent use of this robust diagnostic method would result in more clearly defined, homogeneous samples of women with PMDD, thereby improving the clarity of studies seeking to characterize and treat the underlying pathophysiology of the disorder.

Entities:  

Mesh:

Year:  2016        PMID: 27523500      PMCID: PMC5205545          DOI: 10.1176/appi.ajp.2016.15121510

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  18 in total

1.  Prevalence, incidence and stability of premenstrual dysphoric disorder in the community.

Authors:  H -U Wittchen; E Becker; R Lieb; P Krause
Journal:  Psychol Med       Date:  2002-01       Impact factor: 7.723

2.  Prevalence and predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women. The Harvard Study of Moods and Cycles.

Authors:  Lee S Cohen; Claudio N Soares; Michael W Otto; Bernadette H Sweeney; Rebecca F Liberman; Bernard L Harlow
Journal:  J Affect Disord       Date:  2002-07       Impact factor: 4.839

Review 3.  The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD).

Authors:  Uriel Halbreich; Jeff Borenstein; Terry Pearlstein; Linda S Kahn
Journal:  Psychoneuroendocrinology       Date:  2003-08       Impact factor: 4.905

4.  Daily Record of Severity of Problems (DRSP): reliability and validity.

Authors:  J Endicott; J Nee; W Harrison
Journal:  Arch Womens Ment Health       Date:  2005-09-20       Impact factor: 3.633

5.  Evaluating the criteria used for identification of PMS.

Authors:  Bonnie B Dean; Jeff E Borenstein; Kevin Knight; Kimberly Yonkers
Journal:  J Womens Health (Larchmt)       Date:  2006-06       Impact factor: 2.681

6.  Premenstrual dysphoric disorder: burden of illness and treatment update.

Authors:  Teri Pearlstein; Meir Steiner
Journal:  J Psychiatry Neurosci       Date:  2008-07       Impact factor: 6.186

7.  Criteria for premenstrual dysphoric disorder: secondary analyses of relevant data sets.

Authors:  S Ann Hartlage; Sally Freels; Nathan Gotman; Kimberly Yonkers
Journal:  Arch Gen Psychiatry       Date:  2012-03

8.  Late luteal phase dysphoric disorder in 670 women evaluated for premenstrual complaints.

Authors:  S W Hurt; P P Schnurr; S K Severino; E W Freeman; L H Gise; A Rivera-Tovar; J F Steege
Journal:  Am J Psychiatry       Date:  1992-04       Impact factor: 18.112

9.  Histories of abuse predict stronger within-person covariation of ovarian steroids and mood symptoms in women with menstrually related mood disorder.

Authors:  Tory A Eisenlohr-Moul; David R Rubinow; Crystal E Schiller; Jacqueline L Johnson; Jane Leserman; Susan S Girdler
Journal:  Psychoneuroendocrinology       Date:  2016-02-01       Impact factor: 4.905

10.  Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome.

Authors:  P J Schmidt; L K Nieman; M A Danaceau; L F Adams; D R Rubinow
Journal:  N Engl J Med       Date:  1998-01-22       Impact factor: 91.245

View more
  27 in total

1.  Treatment of premenstrual dysphoria with continuous versus intermittent dosing of oral contraceptives: Results of a three-arm randomized controlled trial.

Authors:  Tory A Eisenlohr-Moul; Susan S Girdler; Jacqueline L Johnson; Peter J Schmidt; David R Rubinow
Journal:  Depress Anxiety       Date:  2017-07-17       Impact factor: 6.505

2.  Making Strides to Simplify Diagnosis of Premenstrual Dysphoric Disorder.

Authors:  C Neill Epperson; Liisa V Hantsoo
Journal:  Am J Psychiatry       Date:  2017-01-01       Impact factor: 18.112

3.  Predictors of premenstrual impairment among women undergoing prospective assessment for premenstrual dysphoric disorder: a cycle-level analysis.

Authors:  K M Schmalenberger; T A Eisenlohr-Moul; P Surana; D R Rubinow; S S Girdler
Journal:  Psychol Med       Date:  2017-02-14       Impact factor: 7.723

4.  Emotion-related impulsivity and rumination predict the perimenstrual severity and trajectory of symptoms in women with a menstrually related mood disorder.

Authors:  Danyelle N Dawson; Tory A Eisenlohr-Moul; Julia L Paulson; Jessica R Peters; David R Rubinow; Susan S Girdler
Journal:  J Clin Psychol       Date:  2017-09-12

Review 5.  Suicide Risk and the Menstrual Cycle: a Review of Candidate RDoC Mechanisms.

Authors:  Sarah A Owens; Tory Eisenlohr-Moul
Journal:  Curr Psychiatry Rep       Date:  2018-10-06       Impact factor: 5.285

6.  Anxiety Disorders Among Women: A Female Lifespan Approach.

Authors:  Liisa Hantsoo; C Neill Epperson
Journal:  Focus (Am Psychiatr Publ)       Date:  2017-04-10

Review 7.  Ovarian Hormones as a Source of Fluctuating Biological Vulnerability in Borderline Personality Disorder.

Authors:  Jessica R Peters; Tory A Eisenlohr-Moul
Journal:  Curr Psychiatry Rep       Date:  2019-10-17       Impact factor: 5.285

8.  Patient Experiences of Health Care Providers in Premenstrual Dysphoric Disorder: Examining the Role of Provider Specialty.

Authors:  Liisa Hantsoo; Husna Sajid; Laura Murphy; Brett Buchert; Jordan Barone; Sabina Raja; Tory Eisenlohr-Moul
Journal:  J Womens Health (Larchmt)       Date:  2021-04-01       Impact factor: 2.681

9.  Response to sertraline is associated with reduction in anxiety-potentiated startle in premenstrual dysphoric disorder.

Authors:  Liisa Hantsoo; Christian Grillon; Mary Sammel; Rachel Johnson; Joanna Marks; C Neill Epperson
Journal:  Psychopharmacology (Berl)       Date:  2021-07-22       Impact factor: 4.530

Review 10.  How to study the menstrual cycle: Practical tools and recommendations.

Authors:  Katja M Schmalenberger; Hafsah A Tauseef; Jordan C Barone; Sarah A Owens; Lynne Lieberman; Marc N Jarczok; Susan S Girdler; Jeff Kiesner; Beate Ditzen; Tory A Eisenlohr-Moul
Journal:  Psychoneuroendocrinology       Date:  2020-10-13       Impact factor: 4.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.